TECENTRIQ Dosing

Q3W dosing for your TECENTRIQ patients 1

IV=intravenous; q3w=every 3 weeks.

  • Do not administer as an IV push or bolus
  • Do not co-administer other drugs through the same IV line

Dosage modifications from the TECENTRIQ Prescribing Information 1

No dose reductions of TECENTRIQ are recommended.

Adverse reaction Severity of adverse reaction* Dosage modifications
Pneumonitis Grade 2 Withhold dose until grade 1 or resolved and corticosteroid dose is less than or equal to prednisone 10 mg per day (or equivalent)
Grade 3 or 4 Permanently discontinue
Hepatitis AST or ALT >3 and ≤8 times ULN or total bilirubin >1.5 and ≤3 times ULN
Withhold dose until grade 1 or resolved and corticosteroid dose is less than or equal to prednisone 10 mg per day (or equivalent)
AST or ALT >8 times ULN or total bilirubin >3 times ULN
Permanently discontinue
Colitis or diarrhea Grade 2 or 3
Withhold dose until grade 1 or resolved and corticosteroid dose is less than or equal to prednisone 10 mg per day (or equivalent)
Grade 4
Permanently discontinue
Endocrinopathies Grade 2, 3, or 4
Withhold dose until grade 1 or resolved and clinically stable on hormone replacement therapy
Other immune-mediated adverse reactions involving a major organ Grade 3 Withhold dose until grade 1 or resolved and corticosteroid dose is less than or equal to prednisone 10 mg per day (or equivalent)
Grade 4 Permanently discontinue
Infections Grade 3 or 4 Withhold dose until grade 1 or resolved
Infusion-related reactions Grade 1 or 2 Interrupt or slow the rate of infusion
Grade 3 or 4 Permanently discontinue
Persistent grade 2 or 3 adverse reaction (excluding endocrinopathies) Grade 2 or 3 adverse reaction that does not recover to grade 0 or 1 within 12 weeks after last TECENTRIQ dose
Permanently discontinue
Inability to taper corticosteroid Inability to reduce to less than or equal to prednisone 10 mg per day (or equivalent) within 12 weeks after last TECENTRIQ dose
Permanently discontinue
Recurrent grade 3 or 4 adverse reactions Recurrent grade 3 or 4 (severe or life-threatening) adverse reactions
Permanently discontinue

ALT=alanine aminotransferase; AST=aspartate aminotransferase; ULN=upper limit of normal.

*National Cancer Institute's Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.0.

Including, but not limited to hypophysitis, adrenal insufficiency, hyperthyroidism, and type 1 diabetes mellitus.